Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

NCT03036150 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03036150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03036150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
February 2, 2017
Completion date
June 12, 2020
Enrollment
4,304 (actual)
Sites
390

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease